Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Retinoblastoma 1Neuroblastoma 1Medulloblastoma 1Glioblastoma 1Carcinoid Tumor 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Biological Factors × Clear all
NCT00314925 2010-02-25

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

Neotropix

Phase 1 Unknown
60 enrolled
CNSEndocrineGenitourinaryOther solid neoplasmSarcoma

Carcinoid Tumor, Glioblastoma, Medulloblastoma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡